Westmont, Illinois 60559

  • Prostate Cancer


This study will investigate health related quality of life factors in patients undergoing low dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel, sexual function and bother will be measured by the EPIC questionnaire at various time intervals.


Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b, N0, M0 - Greater than or equal to 40 years of age - Low and Low- Intermediate Risk prostate cancer - Prostate volumes by TRUS ≤ 60 cc - I-PSS score < 25 (alpha blockers allowed) - Signed study-specific informed consent form prior to study entry Exclusion Criteria: - Lymph node involvement (N1) - Evidence of distant metastases (M1) - Radical surgery for carcinoma of the prostate - Prior pelvic radiation - Major medical or psychiatric illness, which in the investigator's opinion would prevent completion of treatment and would interfere with follow- up or ability to complete questionnaires - Hip prosthesis - Inability or refusal to provide informed consent - Evidence of Previous TURP - Prior hormone therapy - Prior TURP



Primary Contact:

Principal Investigator
Brian J Moran, MD
Chicago Prostate Center

Backup Contact:


Location Contact:

Westmont, Illinois 60559
United States

Brian J Moran, MD
Phone: 630-654-2515
Email: seeds@prostateimplant.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.